반응식
[C:1]1([CH3:13])[CH:6]=[CH:5][CH:4]=[C:3]([N:7]2[CH2:11][CH2:10][NH:9][C:8]2=[O:12])[CH:2]=1.Br[C:15]1[CH:16]=[N:17][CH:18]=[CH:19][C:20]=1[C:21]([F:24])([F:23])[F:22].N[C@@H]1CCCC[C@H]1N.P([O-])([O-])([O-])=O.[K+].[K+].[K+]>[Cu](I)I.O1CCOCC1>[C:1]1([CH3:13])[CH:6]=[CH:5][CH:4]=[C:3]([N:7]2[CH2:11][CH2:10][N:9]([C:15]3[CH:16]=[N:17][CH:18]=[CH:19][C:20]=3[C:21]([F:24])([F:23])[F:22])[C:8]2=[O:12])[CH:2]=1참가 물질
7
반응물 4
생성물 1
시약·촉매·용매 2
실험 절차
Using the same reaction conditions as in Example 14, 1-m-tolyl-imidazolidin-2-one (I-131b: 150 mg, 0.8522 mmol) was reacted with 3-bromo-4-trifluoromethyl-pyridine (160 mg, 0.8522 mmol), 1,4-dioxane (5 mL), copper iodide (16.23 mg, 0.08522 mmol), trans-1,2-diamino cyclohexane (29.27 mg, 0.2552 mmol) and potassium phosphate (542.56 mg, 2.556 mmol) to afford the crude product. Purification by preparative HPLC afforded 94 mg of the product (34.43% yield).
후처리
- customto afford the crude product
- customPurification by preparative HPLC
출처 및 근거
- ORD 기록
- ord-a1bcd68890a641bc8110f29bde673d23
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- USRE045173E1
연결된 노트
불러오는 중…